Minocycline treatment for chronic autoimmune uveitis
The Efficacy and Safety of Minocycline for Chronic Autoimmune Uveitis
This study is testing if minocycline can help people aged 18-60 with chronic autoimmune uveitis reduce inflammation and protect their vision better than current treatments.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05474729 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the efficacy and safety of minocycline in patients suffering from chronic autoimmune uveitis, a severe ocular disease that can lead to blindness. The study aims to address the limitations of current treatments, such as glucocorticoids and immunosuppressants, which often show inadequate results. Participants will receive minocycline to evaluate its potential benefits in reducing inflammation and preserving visual function. The trial is designed for individuals aged 18-60 who have experienced visual impairment due to autoimmune conditions.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-60 diagnosed with autoimmune diseases that have caused visual function damage.
Not a fit: Patients who are allergic to minocycline or currently using glucocorticoids, immunosuppressants, or biologics may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve visual outcomes and quality of life for patients with chronic autoimmune uveitis.
How similar studies have performed: While minocycline has shown promise in other neuro-inflammatory diseases, its application in chronic autoimmune uveitis is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant diagnosed of autoimmune diseases with visual function damage (decrease of BCVA, loss of retinal structure) * Participant aged from 18-60 years old. * Participant that signed the informed consent document and is able to complete the following visits. Exclusion Criteria: * Participant is allergy to minocycline or tetracyclines. * Participant has no contraindications of minocycline or tetracyclines. * Participant has an abnormal function of liver, heart, kidney and thyroid. * Participant is using glucocorticoids, immunosuppressants or biologics. * Female that is pregnant, breast-feeding or planning to become pregnant. * Participant that is currently using other medications for other diseases.
Where this trial is running
Guangzhou, Guangdong
- Zhongshan Ophthalmic Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Principal investigator: Dan Liang — Zhongshan Ophthalmic Center, Sun Yat-sen University
- Study coordinator: Dan Liang
- Email: liangdan@gzzoc.com
- Phone: （86）-87330402
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.